Our Mission
Founded by a father whose son lives with Charcot-Marie-Tooth Disease Type 1A (CMT1A), Shark Tooth is a mission-driven company dedicated to developing treatments for the 1.6 million people worldwide living with CMT1A.
Why now?
The first proof that CMT1A could be treated came in 2017, when an RNA therapy reversed the disease in mice, though the required dose was unsafe for humans.
Since then, RNA science has advanced rapidly, accelerated by the global push during COVID, creating new chemistries and delivery technologies that were unavailable 8 years ago and remain untested for CMT1A.
At the same time, new AI tools now enable much faster development of therapeutic approaches.
Together, these advances make the path to an effective CMT1A treatment more achievable than ever.
What's the impact?
While CMT1A is rare, it's the most common rare disease without any treatment or cure affecting 1.6M people worldwide.
Thanks to government incentives such as the “Orphan Disease Designation”, the TAM for CMT1A is approximately $14B per year in the US alone.
Furthermore, solving CMT1A paves the way for treatments for other peripheral nerve diseases impacting 5M people worldwide.
What's our approach?
We will not reinvent the wheel.
We focus on using what already works. Our goal is not to create new drugs from scratch, but to assemble the right pieces by partnering with leading labs and funding the research needed to test whether their proprietary technologies can be applied to CMT1A.
Rather than making CMT1A the first condition treated with a new platform, we aim for it to be the 10th, building on technologies that have already proven themselves in other diseases.
How can you help?
At this pivotal stage, we need your support to transform our vision into reality.
​
We gratefully welcome both investments and tax-deductible donations to advance our mission.
​
If you’d like to explore ways to contribute or learn more about supporting our efforts, please reach out: apple@sharktooth.bio.
Together, we can make a difference.
Focus on "Drug Assembly"
rather than "New Drug Discovery"
With support from our scientific advisors from Harvard, Johns Hopkins, and leading biotech executives, we've developed a hypothesis on how to accelerate the path to a treatment for CMT1A.
We are convinced that the technology that will lead to the first treatment for CMT1A already exists -- it just hasn't been applied to CMT1A yet.
​
As such, our focus is not on new drug discovery, but rather on what we are calling "Drug Assembly": partnering with labs to fund the research to test if their technology could lead to the first treatment for CMT1A.
Our Partners
